MIMEDX GROUP, INC. 8K

MiMedx Group, Inc. agreed to acquire Sanara MedTech Inc. in a $350 million cash-and-stock merger expected to close by year-end 2026, significantly expanding MiMedx’s surgical business and financial profile.

On July 29, 2026, MiMedx Group, Inc. announced that it entered into a definitive merger agreement to acquire Sanara MedTech Inc. in a cash-and-stock transaction valued at $35 per Sanara share, implying a total enterprise value of approximately $350 million, under which Sanara shareholders will receive $33.00 in cash and 0.4735 shares of MiMedx common stock per Sanara share. The deal, unanimously approved by both companies’ boards, is expected to close by year-end 2026 subject to Sanara shareholder and regulatory approvals and other customary conditions, and will be financed with MiMedx’s cash on hand and a new $300 million term loan from Hayfin Capital Management, LLP, replacing MiMedx’s existing credit facility. Management expects the combination to nearly double MiMedx’s surgical revenue, be immediately accretive to revenue growth, gross margin and adjusted EBITDA margin, generate over $20 million in run-rate cost synergies, and drive combined 2027 revenue to well over $400 million with an adjusted EBITDA margin above 20%, creating a larger regenerative medicine platform across multiple surgical subspecialties and leveraging Sanara’s hospital and surgical distribution network.

Filing Facts

CIK

1376339

Ticker

-

Form

8K

Source Type

sec

Accession

0001376339-26-000070

Alert Tier

8